Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,318 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $6.12, for a total value of $26,426.16. Following the transaction, the insider directly owned 358,411 shares in the company, valued at $2,193,475.32. The trade was a 1.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total value of $376,658.30.
- On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total value of $161,007.20.
- On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total value of $49,587.20.
- On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total value of $41,303.52.
- On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total value of $119,889.25.
- On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total value of $21,261.66.
- On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total value of $22,791.90.
- On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total value of $15,352.00.
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total value of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total value of $66,026.88.
Clene Trading Up 4.0%
CLNN opened at $6.57 on Thursday. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The business's fifty day simple moving average is $5.48 and its 200-day simple moving average is $6.62. The company has a market capitalization of $77.39 million, a price-to-earnings ratio of -2.53 and a beta of 0.62.
Clene (NASDAQ:CLNN - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.14). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. On average, equities research analysts predict that Clene Inc. will post -1.99 EPS for the current year.
Institutional Investors Weigh In On Clene
A number of hedge funds have recently made changes to their positions in the stock. Lunt Capital Management Inc. lifted its stake in shares of Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after purchasing an additional 1,250 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in Clene in the third quarter valued at about $29,000. Geode Capital Management LLC raised its stake in Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company's stock valued at $482,000 after buying an additional 6,090 shares during the last quarter. Jane Street Group LLC purchased a new stake in Clene in the second quarter valued at about $47,000. Finally, State Street Corp raised its stake in Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company's stock valued at $175,000 after buying an additional 17,300 shares during the last quarter. 23.28% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on CLNN. Weiss Ratings restated a "sell (d-)" rating on shares of Clene in a research note on Friday, January 9th. Canaccord Genuity Group restated a "buy" rating and set a $48.00 price objective on shares of Clene in a research note on Friday, March 13th. Finally, D. Boral Capital restated a "buy" rating and set a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $34.00.
View Our Latest Stock Analysis on CLNN
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
